We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

49 hedge funds and large institutions have $75.1M invested in Gyre Therapeutics in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,122% more call options, than puts

Call options by funds: $290K | Put options by funds: $9K

13% more capital invested

Capital invested by funds: $66.2M → $75.1M (+$8.86M)

13% less funds holding

Funds holding: 56 → 49 (-7)

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Holders
49
Holders Change
-7
Holders Change %
-12.5%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
3
Increased
6
Reduced
12
Closed
10
Calls
$290K
Puts
$9K
Net Calls
+$281K
Net Calls Change
+$53K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$1.22M
2
Deutsche Bank
Deutsche Bank
Germany
+$316K
3
Renaissance Technologies
Renaissance Technologies
New York
+$248K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$221K
5
TDC
Thompson Davis & Co
Virginia
+$37.2K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$446K
2
Two Sigma Investments
Two Sigma Investments
New York
-$361K
3
DS
DRW Securities
Illinois
-$342K
4
NCCM
Nine Chapters Capital Management
New Jersey
-$107K
5
VKH
Virtu KCG Holdings
New York
-$107K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$19.8M – – –
NMC
2
NEA Management Company
Maryland
$13.6M – – –
RI
3
RTW Investments
New York
$7.92M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$5.33M +$221K +107 +5%
CCM
5
Camber Capital Management
Massachusetts
$4.63M – – –
BIT
6
BlackRock Institutional Trust
California
$3.4M +$2.07K +1 +0.1%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$2.19M – – –
SCM
8
Sarissa Capital Management
Connecticut
$1.87M – – –
EC
9
EcoR1 Capital
California
$1.84M – – –
Franklin Resources
10
Franklin Resources
California
$1.82M – – –
Fidelity Investments
11
Fidelity Investments
Massachusetts
$1.54M -$33K -16 -2%
ACA
12
Avoro Capital Advisors
New York
$1.39M +$1.22M +592 New
DCM
13
DAFNA Capital Management
California
$1.38M – – –
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$1.34M -$31K -15 -3%
BCM
15
Bridgeway Capital Management
Texas
$1.23M – – –
Deutsche Bank
16
Deutsche Bank
Germany
$868K +$316K +153 +70%
Renaissance Technologies
17
Renaissance Technologies
New York
$761K +$248K +120 +59%
Morgan Stanley
18
Morgan Stanley
New York
$542K +$24.8K +12 +5%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$532K – – –
Bank of New York Mellon
20
Bank of New York Mellon
New York
$369K – – –
Connor, Clark & Lunn Investment Management (CC&L)
21
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$310K – – –
AIA
22
Arbor Investment Advisors
North Carolina
$308K – – –
BFA
23
BlackRock Fund Advisors
California
$244K -$16.5K -8 -7%
California Public Employees Retirement System
24
California Public Employees Retirement System
California
$239K – – –
Goldman Sachs
25
Goldman Sachs
New York
$236K -$55.8K -27 -21%
1
2 3

GYRE Hedge Fund Activity: Q1 2015 in Review

49 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2015, worth a combined $75.1M — up 13% from $66.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GYRE and 3 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 6 added.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $1.22M. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $446K sold.

  • 49 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2015, down from 56 in Q4 2014.
  • Funds reported $75.1M of Gyre Therapeutics stock for Q1 2015, up 13% quarter-over-quarter.
  • 3 funds opened new Gyre Therapeutics positions in Q1 2015 and 10 closed out, a net change of -7 holders.
  • The largest Gyre Therapeutics buyer in Q1 2015 was Avoro Capital Advisors, an estimated $1.22M added.
  • The largest Gyre Therapeutics seller in Q1 2015 was Two Sigma Advisers, an estimated $446K sold.

Based on aggregated 13F filings for Q1 2015.